ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

Home ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

ABI-009 (nab-Sirolimus) Improves Tumor Accumulation and Antitumor Activity over Oral mTOR Inhibitors

/ Publications

Share the Post

About the Author

Related Posts

Aadi Bioscience Breakthrough Therapy nab-Sirolimus (ABI-009)
Aadi Bioscience to Present at the H.C. Wainwright Global Investment Conference
Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 or TSC2 Genes (PRECISION 1)
Aadi Bioscience Announces FDA Acceptance and Priority Review for the New Drug Application of FYARRO™ for the Treatment of Advanced Malignant PEComa
Phase 2, Multicenter Open-label Basket Trial of nab-Sirolimus for Malignant Solid Tumors Harboring Inactivating Alterations in TSC1 or TSC2 (PRECISION I)
Characterizing the genomic landscape of malignant perivascular epithelioid cell family of tumors (PEComa-FT) in a real-world population using the Foundation Medicine genomic database
Aadi Bioscience Appoints Loretta Itri as Chief Medical Officer
Read More
Scott Giacobello, CPA

Comments

Comments are closed.